文献速递甲状腺疾病

放射性碘联合抗甲状腺药物与单药治疗Graves病的疗效比较:随机对照试验的系统评价与荟萃分析

Comparative Efficacy of Radioiodine Therapy With Adjunctive Thionamides vs Either Treatment Alone in the Management of Graves Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该系统评价与荟萃分析纳入21项随机对照试验共1914例成人Graves病患者,比较放射性碘联合抗甲状腺药物与单药治疗的疗效。结果显示联合治疗对成功率和失败率无显著影响,但可提高甲状腺功能正常状态机会并减少甲状腺功能减退。甲巯咪唑单药与放射性碘联合抗甲状腺药物在缓解甲状腺功能亢进方面无显著差异。

要点

  • 放射性碘联合抗甲状腺药物对成功或失败率无显著影响。
  • 联合治疗可提高甲状腺功能正常状态机会并减少甲状腺功能减退。
  • 丙硫氧嘧啶联合放射性碘与成功率降低相关。

核心结论

  • 抗甲状腺药物不影响放射性碘治疗的成功率或失败率,尤其在长期随访中。
  • 抗甲状腺药物可能改善甲状腺功能正常结局并减少甲状腺功能减退。
  • 长期抗甲状腺药物单药治疗与放射性碘在缓解甲状腺功能亢进方面无显著差异。

研究设计与样本

  • 系统评价与荟萃分析,纳入21项随机对照试验,共1914例成人Graves病患者。
  • 采用随机效应模型估计合并相对风险,使用GRADE评估证据确定性。

主要发现

  • 辅助抗甲状腺药物对成功率无显著影响(RR:0.96,95%CI:0.91-1.01)。
  • 辅助抗甲状腺药物对失败率无显著影响(RR:1.17,95%CI:0.97-1.42),证据确定性为中等。
  • 与放射性碘相比,辅助抗甲状腺药物提高甲状腺功能正常状态机会并减少甲状腺功能减退(RR:0.67,95%CI:0.50-0.90)。
  • 抗甲状腺药物单药与放射性碘联合抗甲状腺药物在缓解甲状腺功能亢进方面无显著差异(RR:0.93,95%CI:0.84-1.02)。
  • 丙硫氧嘧啶联合放射性碘与成功率降低相关(RR:0.81,95%CI:0.69-0.96)。

临床怎么用

  • Graves病管理需个体化医患决策。
  • 辅助抗甲状腺药物可能用于改善甲状腺功能正常结局并减少甲状腺功能减退。

局限性

  • 需要额外的长期试验来确认抗甲状腺药物单药与放射性碘比较的发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Antithyroid drugs (ATDs) and radioactive iodine (RAI) are the main nonsurgical modalities for Graves disease, but there is no agreement on the optimal approach for utilizing these 2 alternatives, either individually or in combination. OBJECTIVE: This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the success (hypothyroidism/euthyroid) and failure (hyperthyroidism/relapse) of adjunctive (pre-RAI/post-RAI/both) and monotherapy with ATDs in Graves disease. METHODS: PubMed, CENTRAL, Scopus, and Web of Science were searched to December 2023 for RCTs on adjunctive ATDs with RAI or ATDs monotherapy in adults. Pooled relative risks were estimated using a random-effects model. Certainty of findings was assessed with GRADE. RESULTS: We included 21 RCTs (1914 participants). Adjunctive ATDs showed no significant effect on success (RR: 0.96, 95% CI: 0.91-1.01) or failure (RR: 1.17, 95% CI: 0.97-1.42) rate (moderate GRADE) but increased the chance of euthyroid state and reduced hypothyroidism (RR: 0.67, 95% CI: 0.50-0.90) compared to RAI. ATDs monotherapy vs RAI with adjunctive ATDs showed no significant difference in resolving hyperthyroidism (RR: 0.93, 95% CI: 0.84-1.02). Propylthiouracil with RAI was associated with reduced likelihood of success (RR: 0.81, 95% CI: 0.69-0.96). CONCLUSION: ATDs do not significantly affect the success or failure rates of RAI therapy, particularly in long-term follow-up, but they may improve euthyroid outcomes and reduce hypothyroidism. Long-term ATD monotherapy showed no significant difference compared with RAI in resolving hyperthyroidism; however, additional long-term trials are needed to confirm these findings. Management of Graves disease requires individualized physician-patient decisions.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mirjalili SR, Razmpoosh E, Eshraghi R, et al. Comparative Efficacy of Radioiodine Therapy With Adjunctive Thionamides vs Either Treatment Alone in the Management of Graves Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2026. PMID: 41324316. doi:10.1210/clinem/dgaf580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。